• BSE
  • NSE
    • {{d.cmpname}}
    • {{d.price}}
    • ({{d.PerChg}}%)
Equity | News | Hot Pursuit
Hot Pursuit
Aarti Drugs Q3 PAT slides 37% YoY to Rs 37 cr
(13:50, 28 Jan 2023)

Net sales stood at Rs 663.96 crore in the quarter ended 31 December 2022, up 4.6% from Rs 634.80 crore reported in the corresponding quarter previous year.

Consolidated profit before tax dropped 36.9% to Rs 49.68 crore in Q3 FY23 as agasint Rs 78.69 crore recorded in Q3 FY22. Total expenses was at Rs 615.30 crore in Q3 FY23, rising 9.33% year on year (YoY)

EBITDA fell 26% YoY to Rs 71.7 crore in the quarter ended 31 December 2022. EBITDA Margin reduced by 443 basis points to 10.8% as compared with 15.2% reported in Q3 FY22.

The company's revenue from API business stood at Rs 557.3 crore (up 9% YoY), revenue from Formulation segment was at Rs 49.9 crore (down 9% YoY) and revenue from Specialty Chemicals, Intermediates & Others stood at Rs 57.1 crore (down 14% YoY) during the period under review.

On standalone basis, the company's net profit declined 34.3% to Rs 36.71 crore despite of 5.4% rise in revenue to Rs 625.53 crore in Q3 FY23 over Q3 FY22. The standalone business contributed around 92% to the consolidated revenue for the quarter.

Domestic revenue grew approximately by 8% while exports grew by around 2% YoY for Q3 FY23.

Adhish Patil, chief financial officer of Aarti Drugs, said, “The company's overall API revenue for the quarter grew by 9% YoY. However, due to a correction in raw material prices, the company made some price adjustments in order to defend its market share. Owing to API price correction, the company undertook inventory loss of approximately Rs 6 crore as a prudent practice. All of this weighed on the gross margins by almost ~100 bps during the quarter.

The company has increased the inventory levels of imported key starting materials (KSMs) and other raw materials due to a sudden spike of Covid-19 cases and holidays related to a new year in China. API sales volume in exports were affected to some extent due to shortage of US Dollar in many countries. The finance cost also increased due to higher working capital requirements and rising interest rates.

The company has already received commitments from the customers for the brownfield expansion products as well as has received committed line of order for a campaign based product. As a result, the company is eyeing to double the revenue from Specialty Chemicals business within the next 12 months through the ongoing brownfield expansion.

The capex for 9M FY23 stood at Rs 115 crore and is expected to be in the range of Rs 200-250 crore for the entire FY23. The company's various capex initiatives are expected to be completed and fully scaled up over the period of next 2 years in a phased manner and are expected to bolster the topline and profitability growth.”

Meanwhile, the company's board has declared the Interim Dividend of Re 1 for the financial year 2022-23. The record date for the same has been fixed on Wednesday, 8 February 2023.

Aarti Drugs is primarily involved in manufacturing and marketing of active pharmaceutical ingredients (API), pharma intermediates and specialty chemicals.

Shares of Aarti Drugs rose 1.10% to close at Rs 410.55 on Friday, 27 January 2023.

Powered by Capital Market - Live News

.
Stock Broker Name Registration Number Registered Address Branch Address Contact Number Email id
DB (International) Stock Brokers Limited INZ000179035 (BROKING)

IN-DP-CDSL-266-2004 (DEPOSITORY)
Unit No. 210/211/211A at 2nd floor, Dalal Street Commercial Cooperative Society Ltd, Block No.53, Zone 5, Gift City, Gandhinagar, Gujarat-382355 Head Office – 114, New Delhi House, 27 Barakhamba Road, Delhi 110001 011-43606162 compliance@dbonline.in
51, Mini Market T/F Mandir Wali Gali, Yusuf Sarai, New Delhi 110016 011-35936102 greenpark@dbonline.in
C-12, DB Plaza, RDC Raj Nagar, Ghaziabad 2012002 0120-4150393 ghaziabad@dbonle.in
827, Tower B3, Spaze I Tech Park, Sector 49, Sohna Road, Gurgaon, Haryana – 122001 0124-4383584 sanjay05@dbonline.in
Plot No 4, Wasme House, Film City Sector 16A, Noida – 201301 0120-4823200 compliance@dbonline.in
Out Side Jassusar Gate, Bikaner, Rajasthan – 334001 9001643408 bikaner@dbonline.in
Office No 101, City Center, Opp. High Court, M G Road, Indore 452001 9424083019 brajeshsadani@dbonline.in
203, Marshal House 25, Strand Road, Kolkata 700001 033-40055270 b032@dbonline.in
Shop No.-7, 2nd Floor, Amar Complex, Opp. Hanumaan Mandir, The Mall, Solan- 173212 6230604596 parwanoo@dbonline.in
Daga Commodities Private Limited INZ000028833 114, New Delhi House, 27 Barakhamba Road Delhi New Delhi DL 110001- 0120-4823200 compliance@dbonline.in
DAGA BUSINESS (INTERNATIONAL) STOCK BROKERS IFSC PRIVATE LIMITED - Unit No. 228, Signature Building, Second Floor, Block 13B, Zone-1, GIFT SEZ, Gandhinagar,Gujarat 382355 - 0120-4823200 compliance@dbonline.in
Investor Grievances Email ID: investors@dbonline.in
Copyright © 2016 All rights Reserved DB (International) Stock Brokers Ltd.     Designed, Developed and content powered by C-MOTS Infotech( ISO 9001:2015 certified )
"KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."         "Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL on the same day......................issued in the interest of investors."          "No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
Attention Investors ::
subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries | Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 01, 2020. | Update your email id and mobile number with your stock broker / depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge. | Check your securities / MF / bonds in the consolidated account statement issued by NSDL/CDSL every month........... Issued in the interest of Investors"